Molecular staging of lung and esophageal cancer

Surgical Clinics of North America

Volumn 82, Issue 3, 2002, Pages 497-523

  Lau, Christine L ^a   Moore, Mary Beth H ^a   Brooks, Kelly R ^a   D'Amico, Thomas A ^a   Harpole Jr , David H ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; MOLECULAR MARKER; SCLEROPROTEIN;

CANCER INVASION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS; MOLECULAR BIOLOGY; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGEAL NEOPLASMS; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 0036620734     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00024-5     Document Type: Review

References (139)

1. Casson AG, McCart JA. Genetic modulation in the pathogenesis and treatment of cancer. Chest Surg Clin N Am 1995;5:17-37.
2. Casson AG. Esophageal cancer: biology. In Pearson FG, Hiebert CA, Deslauriers J, et al, editors. Esophageal surgery. New York: Churchill Livingston; 1996. p. 953-9.
3. Roth JA. The cell and the molecular biology of esophageal carcinoma. Chest Surg Clin N Am 1994;4:205-15.
4. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
5. Rusch VW, Dmitrovsky E. Molecular biologic features of non-small cell lung cancer: clinical implications. Chest Surg Clin N Am 1995;5:39.
6. Slebos RJC, Kibbelaar R, Dalesio I, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561.
7. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997;75:1125.
8. Harada M, Dosaka-Akita H, Miyamoto H, et al. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69:72.
9. Nemunaitis J, Klemow S, Tong A, et al. Prognostic value if K-ras mutations, ras oncoprotein and c-erb B-2 oncoprotein expression on adenocarcinoma of the lung. Am J Clin Oncol 1998;21:155.
10. Trautmann B, Wittekind C, Strobel D, Meixner H, Keymling J, Gossner L, et al. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Eur J Gastroent Hepat 1996;8(8):799-804.
11. Lord RV, O'Grady R, Sheehan C, Field AF, Ward RL. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroent Hepat 2000;15(7):730-6.
12. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Onc 1999;17(11):3631-52.
13. Pfeiffer P, Nexo E, Bentzen SM. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features, and prognosis. Br J Cancer 1998;78:96.
14. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic non-small cell lung cancer. Eur J Cancer 1996;32A:2070.
15. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer. Am J Respir Crit Care Med 1998;157:1093.
16. Pastorino U, Andreola S, Tagliabue E, et al. Immunohistochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997;15:2858.
17. D'Amico TA, Massey M, Herndon JE II, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients using 10 molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.
18. Lynch TJ Jr. Lung cancer highlights. Oncologist 2000;5(4):274-9.
19. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17(10):3188-94.
20. Kern JA, Schwartz DA, Nordberg JE, et al. P185neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res 1990;50:5184.
21. Harpole DH Jr, Herndon JE II, Young WG, Wolf WG, Sabiston DC Jr. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995a;55:51.
22. Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of e-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27:1372.
23. Harpole DH, Richards WG, Herndon JE, et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470.
24. Hardwick RH, Barham CP, Ozua P, et al. Immunohistochemical detection of p53 and c-erb-B2 in oesophageal carcinoma. Eur J Surg Oncol 1996;23:30-5.
25. Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE II, D'Amico TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72(3):859-66.
26. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362(6423):849-52.
27. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert H. Expression of aoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998;4:2991-7.
28. Szak ST, Pietenpol JA. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J Biol Chem 1999;274(6):3904-9.
29. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Hematol/Oncol Clin N Am 1997;1:409.
30. Kwiatkowski DJ, Harpole DH, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468.
31. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828.
32. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995;76:2457.
33. Harpole DH Jr, Marks JR, et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Canc Res 1995c;1:659.
34. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primarily resected non-small cell lung cancer. Cancer Res 1993;53:1.
35. Mitsudomi T, Oyama T, Kusano T, et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Canc Inst 1993;85:2018A.
36. McLaren R, Kuzu I, Dunnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735.
37. Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;13:1893.
38. Passlick B, Izbicki JR, Haussinger K, et al. Immunohistochemical detection of p53 is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Cardiovasc Surg 1995;109:1205.
39. Carbone DP, Minna JD. Molecular biology of lung cancer. In: Molecular foundations of oncology. Broder S, editor. Baltimore: Williams and Wilkins; 1991. p. 79.
40. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression in an independent prognostic parameter in node-negative non small cell lung carcinoma. J Pathol 1996;178:53.
41. Casson AG, Tammenagi M, Eskandarian S, et al. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Clin Mol Pathol 1998;51:71-9.
42. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
43. Cawley HM, Meltzer SJ, DeBeneditti VMG, et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998;115:19-27.
44. Kim R, Clarke MR, Melhem MR, et al. Expression of p53, PCNA, and c-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997;42:2453-62.
45. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220-8.
46. Seir C, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
47. Younes M, Ertan A, Lechago LV, et al. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
48. Jones DR, Davidson AG, Summer CL, et al. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 1994;57:598-603.
49. Sarbia M, Porschen R, Borchard F. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
50. Patel DD, Bhatavdekar JM, Chikhlikar PR, et al. Clinical significance of p53, nm23, and bcl-2 in T2-N1M0 oesophageal carcinoma: An immunohistochemical approach. J Surg Oncol 1997;65:111-6.
51. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of spoptotic cell death. Cell 1993;74(4):597.
52. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom B, Avery BJ, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with bcl-2 family proteins and interacts with viral and cellular survival promoting proteins. Oncogene 1995;11:921.
53. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B. Jestramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993;53:4573.
54. Oltavi ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74(4):609-19.
55. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690.
56. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003.
57. Takayama T, Nagao M, Sawada H, Yamada Y, et al. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol 2001;78:116-23.
58. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30(1):3-21.
59. Morris CD. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroent 2001;96(4):990-6.
60. Souza RF. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Canc Res 2000;60(20):5767-72.
61. Xu H-J, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Canc Inst 1994;86:695.
62. Reissman PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma gene in non-small cell lung cancer. Oncogene 8;1913:1993.
63. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415.
64. Landberg G, Nielsen NH, Nilsson P, Emdin SO, Cajander J, Roos G. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 1997;57:549-54.
65. Hara H, Yamashita K, Shinada J, Yoshimura H, Kameya T. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 2001;34(2):219-26.
66. Takubo K, Nakamura K, Izumiyama N, et al. Telomerase activity in esophageal carcinoma. J Surg Oncol 1997;66:88-92.
67. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastroint Surg 2000;4(2):135-42.
68. Pence JC, Kerns BM, Dodge RK, et al. Prognostic significance of the proliferation index in surgically-resected non-small cell lung cancer. Arch Surg 1993;128:1382.
69. Ishida T, Kaneko S, Akazawa K, et al. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993;53:5000.
70. Harpole DH, Herndon JE, Young WG, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995b;76:787.
71. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small cell lung cancer? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg 1993;106:90.
72. Volm M, Hahn EW, Mattern J, et al. Five year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988;48:2923.
73. Schmidt RA, Rusch VW, Piantadosi S. A flow cytometry study of non-small cell lung cancer classified as T1N0. Cancer 1992;69:78.
74. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1, 1889.
75. Macchiarini P, Fontanini GM, Hardin MJ, et al. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;3240:145.
76. Duarte I, Buflin BL, Pennington MF, et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998 115:652.
77. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung cancer. J Natl Canc Inst 1997;89:881.
78. Matsuyama K, Chiba Y, Sasaki M, et al. Tumor angiogenesis as a prognostic marker in operable non-small cell lung carcinoma. Ann Thorac Surg 1998;65:1405.
79. Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in nonsmall-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007.
80. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for antitumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Can Met Reviews 1999;18(4):473-81.
81. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated nonsmall-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000;18(1):131-5.
82. Anderson IC, Sugarbaker DJ, Ganju RK, et al. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 1995;55:4120.
83. Yoshino H, Endo Y, Watanabe Y, et al. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 1998;78:833.
84. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor and type I plasminogen activator inhibitor in lung cancer. Cancer Res 1994;54:4671-5.
85. Pappot H, Hoyer-Hasen G, Ronne E, Hansen H, Brunner N, Dano K, Grondahl-Hansen J. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997;33(6):867-72.
86. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE II, Kinch MS, Harpole DH Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001;72(4):1144-8.
87. Sukoh N, Abe S, Ogura S, et al. Immunohistochemical study of cathepsin B: prognostic significance in human lung cancer. Cancer 1994;74:46.
88. Mori M, Kohli A, Baker SP, et al. Laminin and cathepsin B as a prognostic factor in stage I non-small cell lung cancer: are they useful? Modern Pathol 1997;10:572.
89. Hirata T, Fukuse T, Naiki H, et al. Expression of CD44 variant exon 6 in stage I nonsmall cell lung carcinoma as a prognostic factor. Cancer Res 1998;58:1108.
90. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A-a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 1991;324:1084.
91. Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Le/Le antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992;327:14.
92. Matsumoto H, Muramatsu H, Shimotakahara T, et al. Correlation of expression of AABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 1993;72:75.
93. Dresler CM, Ritter JH, Wick MR, et al. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg 1995;59:069.
94. Jones P. DNA methylation and cancer. In: Bertino JR, editor-in-chief. Encyclopaedia of Cancer, vol. 1. San Diego: Academic Press; 1996. p. 501-7.
95. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999;286 (5439):481-6.
96. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
97. Baylin S, Herman J, Graff J, Vertino P, Issa J. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
98. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993;90(24):11995-9.
99. Macleod D, Ali R, Bird A. An alternative promoter in the mouse major histocompatibility complex class II I-Abeta gene: implications for the origin of CpG islands. Mol Cell Biol 1998;18(8):4433-43.
100. Eng C, Herman J, Baylin S. A bird's eye view of global methylation. Nat Gen 2000;24:101-2.
101. Herman J, Umar A, Polyak K, Graff J, Ahuja N, Issa J, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carceinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
102. Esteller M, Corn P, Urena J, Gabrielson E, Baylin S, Herman J. Inactivation of Glutathione s-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998;58:4515-8.
103. Esteller M, Hamilton S, Burger P, Baylin S, Herman J. Inactivation of the DNA repair gene O6-Methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999a;59:793-7.
104. Kohno R, Kawanishi M, Inazawa J, Yokota J. Identification of CpG islands hypermethylated in human lung cancer by the arbitrarily primed-PCR method. Hum Genet 1998;102:258-64.
105. Makos M, Nelkin B, Chazin V, Cavenee W, Broduer G, Baylin S. Regional DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res 1993a;53:2715-8.
106. Makos M, Nelkin B, Lerman M, Latif F, Zbar B, Baylin S. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 1992;89:1929-33.
107. Makos M, Nelkin B, Reiter R, Gnarra J, Brooks J, Isaacs W, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 1993b;53:2719-22.
108. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999;9:349-57.
109. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001;7(7):1998-2004.
110. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61(1):249-55.
111. Merlo A, Herman J, Mao L, Lee D, Gabrielson E, Burger P, et al. 5" CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDNKN2/MTS1 in human cancers. Nat Med 1995;1(7):686-92.
112. Bachman K, Herman J, Corn P, Merlo A, Costello J, Cavenee W, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
113. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. Correlation between the methylation status of the p16/CDKN2 gene and the expression of tp16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998;79:215-20.
114. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92(18):1511-6.
115. Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Onc. 2001;19(2):277-81.
116. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001;20(27):3528-32.
117. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 2001;20(14):1765-70.
118. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61(22):8284-9.
119. Shi HX, Tsao SW, Lam KY, Srivastava G, Liu Y, Wong YC, et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001;173(1):71-8.
120. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, Wu TT. Frequent hypermethylation of the 5′ CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 2001;7(9):2765-9.
121. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60(18):5021-6.
122. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci US 1998;95(20):11891-6.
123. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo G, Koch W, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
124. Wong I, Lo Y, Ahang J, Liew C, Ng M, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver patients. Cancer Res 1999;59:71-3.
125. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin S, Herman J. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999b;59:67-70.
126. Kawakami K, Brabender J, Lord RV, Greenwald BD, Krasna MJ, Yin J, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Can Inst 2000;92(22):1805-11.
127. Salerno C, Frizelle S, Niehans G, et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest 1998;113:1526.
128. Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastases in operable non-small-cell lung cancer. Cancer Res 1993;53:1027.
129. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells is lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994;12:1827.
130. Pantel K, Izbicki JR, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347:649.
131. Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997;144:535.
132. Dobashi K, Sugio K, Osaki T, et al. Micrometastatic p53-positive cells in the lymph nodes of patients with stage I non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 1997;114:339.
133. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415.
134. Von Brevern MC, Hollstein MC, Cawley HM, et al. Circulation ant-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996;56:L4917-21.
135. Luketich JD, Kassis ES, Shriver SP, et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg 1998;66:1715-8.
136. Glickman JN, Torres C, Wang HH, et al. The prognostic significance of lymph node micrometastases in patients with esophageal carcinoma. Cancer 1999;85:769-78.
137. Izbicki JR, Hosch SB, Pichlmeier W, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-94.
138. Sarbia M, Bittinger F, Grabellus F, Verreet P, Dutkowski P, Willers R, Gabbert HE. Expression of Bax, a pro-apoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Intl J Cancer 1997;73(4):508-13.
139. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: A prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996;111:323-33.